NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...
The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...
At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...
N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...
Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in ...
Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Meanwhile, WuXi Vaccines, a subsidiary of WuXi Biologics, says it will sell a vaccine facility in Dundalk, Ireland, to the US drugmaker Merck & Co. for $521 million. WuXi Biologics says the sale ...
According to the latest study from BCC Research, the demand for Conventional and Alternative Pain Treatment Markets is expected to grow from $96.2 billion in 2024 to $144.2 billion by the end of 2029, ...
Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback